GlassScriptPhysician profile
Donna Mason
NPI 1023454840
$3,296.72
in general payments reported to CMS, 2019-2025
24 companies · $771 in 2025
The $771 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $466 · 2023: $1,002 · 2024: $1,057 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,830.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $737.49 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $500.79 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $496.08 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.32 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $190.30 | 2023-2025 | |
| Pfizer INC. | $184.97 | 2022-2025 | |
| Exact Sciences Corporation | $162.53 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $89.99 | 2022-2024 | Trintellix |
| Esperion Therapeutics, INC. | $88.76 | 2023-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $77.48 | 2022-2023 | |
| Amgen INC. | $73.84 | 2023-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $69.94 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $66.98 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $30.08 | 2022-2023 | Gardasil 9, Vaxneuvance |
| Philips North America LLC | $23.68 | 2024 | (Ak6) Vest Therapy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.48 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.42 | 2022 | |
| Inspire Medical Systems, INC. | $21.34 | 2025 | Inspire |
| Azurity Pharmaceuticals, INC. | $20.94 | 2024 | Edarbi |
| Shield Therapeutics INC | $19.40 | 2024 | |
| Abbott Laboratories | $19.11 | 2025 | Freestyle Libre 3 |
| Tonix Medicines, INC. | $19.08 | 2025 | Tonmya |
| Xeris Pharmaceuticals, INC. | $17.53 | 2022 | |
| Almatica Pharma LLC | $17.19 | 2023 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.